APX 3330

Drug Profile

APX 3330

Alternative Names: APX3330; E-3330

Latest Information Update: 10 Jun 2017

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Developer Apexian Pharmaceuticals
  • Class Antivirals; Hepatoprotectants; Quinones; Small molecules
  • Mechanism of Action DNA apurinic apyrimidinic site lyase inhibitors; Protein inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Cancer; Haematological malignancies; Peripheral nervous system diseases; Solid tumours
  • Discontinued Liver disorders

Most Recent Events

  • 06 Jun 2017 Apexian Pharmaceuticals receives SBIR and STTR grant from National Cancer Institute for APX 3330 development in Cancer
  • 01 Mar 2017 The US FDA accepts a protocol for a phase I trial of APX 3330 in Solid tumours to include biomarker measurements and evaluate the tolerability and anti-tumour effects of APX 3330
  • 07 Feb 2017 Preclinical trials in Age-related macular degeneration in USA (unspecified route) (Apexian Pharmaceuticals pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top